Literature DB >> 12790806

Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo.

K J Starkey1, A Janezic, G Jones, N Jordan, G Baker, M Ludgate.   

Abstract

The thyrotrophin receptor (TSHR) provides an autoantigenic link between the thyroid and orbit in Graves' (GD) and thyroid eye diseases (TED). We measured TSHR transcripts in different fat depots to determine whether TSHR expression levels are influenced by the autoimmune/inflammatory process and/or thyroid hormone status, using quantitative real-time PCR. Nine intact or fractionated adipose samples, from patients with GD and/or TED, were analysed ex vivo. Eight expressed the TSHR, at levels approaching the thyroid, and one was at the limit of detection. Thirteen/fifteen orbital and abdominal fat samples from patients free of GD and TED, measured ex vivo, were negative for TSHR transcripts and two were at the limit of detection. All preadipocyte samples induced to differentiate in vitro expressed the TSHR. To investigate the influence of thyroid hormone status on adipose TSHR expression, we induced hyper- and hypothyroidism in BALBc mice by administering tri-iodothyronine and propylthiouracil respectively. In euthyroid animals, whole fat samples were at the limit of detection and were not altered by thyroid hormone status. The results show that adipose TSHR expression ex vivo indicates adipogenesis in progress in vivo and is associated with the autoimmune/inflammatory process in GD and TED but is not restricted to the orbit or influenced by thyroid hormone status.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12790806     DOI: 10.1677/jme.0.0300369

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  33 in total

1.  Fibroblasts expressing the thyrotropin receptor overarch thyroid and orbit in Graves' disease.

Authors:  Terry J Smith; Dolly A Padovani-Claudio; Ying Lu; Nupur Raychaudhuri; Roshini Fernando; Stephen Atkins; Erin F Gillespie; Andrew G Gianoukakis; Barbra S Miller; Paul G Gauger; Gerard M Doherty; Raymond S Douglas
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

2.  Effects of prostaglandin F(2α) on adipocyte biology relevant to graves' orbitopathy.

Authors:  Mohd Shazli Draman; Fiona Grennan-Jones; Lei Zhang; Peter N Taylor; Tommy Kyaw Tun; John McDermott; Paul Moriarty; Daniel Morris; Carol Lane; Seamus Sreenan; Colin Dayan; Marian Ludgate
Journal:  Thyroid       Date:  2013-11-04       Impact factor: 6.568

Review 3.  Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment.

Authors:  James A Garrity; Rebecca S Bahn
Journal:  Am J Ophthalmol       Date:  2006-07       Impact factor: 5.258

Review 4.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

5.  [Calculation of orbital fat volumes for determining treatment timing for thyroid- associated ophthalmopathy].

Authors:  Wei Jiang; Qiu-Yue Cai; Zhang-Fang Li; Zhi-Yi Chen; Yao-Sheng Luo; Shi-di Hu; Jie Shen
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-05-20

Review 6.  Immunopathogenesis of thyroid eye disease: emerging paradigms.

Authors:  Vibhavari M Naik; Milind N Naik; Robert A Goldberg; Terry J Smith; Raymond S Douglas
Journal:  Surv Ophthalmol       Date:  2010 May-Jun       Impact factor: 6.048

7.  A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts.

Authors:  Seema Kumar; Reagan Schiefer; Michael J Coenen; Rebecca S Bahn
Journal:  Thyroid       Date:  2010-01       Impact factor: 6.568

8.  Serum concentrations of adiponectin and resistin in hyperthyroid Graves' disease patients.

Authors:  L Sieminska; D Niedziolka; A Pillich; B Kos-Kudla; B Marek; M Nowak; H Borgiel-Marek
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

9.  Update on the medical treatment of Graves' ophthalmopathy.

Authors:  Gregory J Griepentrog; James A Garrity
Journal:  Int J Gen Med       Date:  2009-12-29

10.  Gsalpha signalling suppresses PPARgamma2 generation and inhibits 3T3L1 adipogenesis.

Authors:  Lei Zhang; Carol Paddon; Mark D Lewis; Fiona Grennan-Jones; Marian Ludgate
Journal:  J Endocrinol       Date:  2009-05-21       Impact factor: 4.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.